Drug Profile
JNJ 63871860
Alternative Names: E coli bioconjugate vaccine - GSK/Johnson & Johnson Innovative Medicine; Escherichia-coli-vaccine-GSK/Johnson & Johnson Innovative Medicine; Expec 4v Conjugate; ExPEC vaccine - GSK/Johnson & Johnson Innovative Medicine; ExPEC-4V; Extra-intestinal pathogenic Escherichia coli vaccine - GSK/Johnson & Johnson Innovative Medicine; JNJ-1860; JNJ-63871860; JNJ-860/EcoXyn-4VLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlycoVaxyn
- Developer GlycoVaxyn; Johnson & Johnson Innovative Medicine
- Class Conjugate vaccines; DNA vaccines; Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Escherichia coli infections; Urinary tract infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 02 Oct 2019 Immunogenicity and safety data from a phase II trial in Escherichia coli infections presented at the IDWeek (IDW-2019)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Escherichia-coli-infections(Prevention, In volunteers) in Japan (IM, Injection)